Auro.Ai Stock Pitch: Long Dr Reddy's (DRREDDY on NSE) - Covid Portfolio is Key for Stock to Perform

Dr Reddy's Labs expects to commercialize all 250m Covid-19 doses in the next 12 months to meet their EBITDA aspirations and will offset continued base portfolio erosion in the US despite a slew of new launches in FY21. Sharp slowdown in India growth which was attributed to a soft anti-infective season in 4Q. Good cost control in line with expectations with COGS improving by 200bps+ YoY and R&D savings by 80bps without compromising product filing rate across markets. Hence, Harshvardhan is bullish on the stock.
Disclaimer: This video reflects the individual views of our users NOT
the views of Auro.Ai.

It is NOT intended to serve as Financial or Investment Advice.